| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/11/2004 | WO2004019956A1 Organophosphorous compounds for the treatment of helminthic infections |
| 03/11/2004 | WO2004019955A1 The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
| 03/11/2004 | WO2004019954A1 Estrogen replacement regimen |
| 03/11/2004 | WO2004019953A1 Therapeutic treatment methods |
| 03/11/2004 | WO2004019952A1 Use of prostacyclin and analogs thereof for improving venous flow |
| 03/11/2004 | WO2004019951A1 REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS |
| 03/11/2004 | WO2004019949A1 Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders |
| 03/11/2004 | WO2004019948A1 New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-d]pyrimidine |
| 03/11/2004 | WO2004019947A1 Alpha-7 nicotinic receptor agonists and statins in combination |
| 03/11/2004 | WO2004019946A1 Inhibitors for excessive accumulation of sodium ion in cells |
| 03/11/2004 | WO2004019945A1 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
| 03/11/2004 | WO2004019944A1 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
| 03/11/2004 | WO2004019942A1 Inverse agonists acting at virus-encoded g protein-coupled receptors |
| 03/11/2004 | WO2004019941A1 Glycinamide derivatives as raf-kinase inhibitors |
| 03/11/2004 | WO2004019940A1 Method of preventing or treating atherosclerosis or restenosis |
| 03/11/2004 | WO2004019939A1 Method of preventing or treating atherosclerosis or restenosis |
| 03/11/2004 | WO2004019937A1 Pharmaceutical composition of metaxalone with enhanced oral bioavailability |
| 03/11/2004 | WO2004019936A1 Peroxynitrite rearrangement catalysts used for the treatment or prophylaxis of diseases caused by peroxynitrite-mediated reactions |
| 03/11/2004 | WO2004019934A1 Use of triptans as antiviral agents |
| 03/11/2004 | WO2004019933A1 Method of preventing or treating atherosclerosis or restenosis |
| 03/11/2004 | WO2004019932A1 Method of preventing or treating atherosclerosis or restenosis |
| 03/11/2004 | WO2004019931A1 Method to treat laminitis and reduce dietary intake for horses |
| 03/11/2004 | WO2004019930A1 Pasting agent |
| 03/11/2004 | WO2004019929A1 Composition based on triethyl citrate for the treatment of bacterial infections of the skin |
| 03/11/2004 | WO2004019928A1 Therapeutic agent for hepatic disease |
| 03/11/2004 | WO2004019927A2 Perfluorinated fatty acids for the treatment of obesity, diabetes, hyperlipidaemia, cancer and inflammation |
| 03/11/2004 | WO2004019926A1 Preventive and/or therapeutic agent for heart failure |
| 03/11/2004 | WO2004019925A1 Oral liquid tolterodine composition |
| 03/11/2004 | WO2004019923A1 Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries |
| 03/11/2004 | WO2004019922A1 Breath freshening and oral cleansing product using citral |
| 03/11/2004 | WO2004019921A2 Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases |
| 03/11/2004 | WO2004019917A1 Device for release of a drug containing oseltamivir and a h1 antagonist |
| 03/11/2004 | WO2004019916A1 Vesicle-encapsulated corticosteroids for the treatment of cancer |
| 03/11/2004 | WO2004019915A1 Vesicle-encapsulated corticosteroids for the treatment of cancer |
| 03/11/2004 | WO2004019914A1 Lipid-polymer-conjugates compositions comprising corticosteroids for the treatment of cancer |
| 03/11/2004 | WO2004019912A2 Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| 03/11/2004 | WO2004019911A2 Buccal, polar or non-polar spray or capsule containing drugs for treating endocrine disorders |
| 03/11/2004 | WO2004019910A2 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
| 03/11/2004 | WO2004019909A2 Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| 03/11/2004 | WO2004019907A1 Methods and reagents for treating infections of clostridium difficile and diseases associated therewith |
| 03/11/2004 | WO2004019905A1 Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
| 03/11/2004 | WO2004019904A1 Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
| 03/11/2004 | WO2004019903A1 Buccal, polar and non-polar spray or capsule containing drugs fortreating metabolic disorders |
| 03/11/2004 | WO2004019902A1 Adhesive gel composition for iontophoresis preparation and process for producing the same |
| 03/11/2004 | WO2004019901A2 Sustained release pharmaceutical composition |
| 03/11/2004 | WO2004019900A1 Preventing or treating epithelial tissue damage or hair loss |
| 03/11/2004 | WO2004019892A2 Drug delivery system for treating urinary incontinence |
| 03/11/2004 | WO2004019891A2 Methods and compostions for immune tolerance |
| 03/11/2004 | WO2004019889A2 Inhibitors of post-amadori advanced glycation end products |
| 03/11/2004 | WO2004019888A2 Process to prepare psorospermin |
| 03/11/2004 | WO2004019884A2 Agents and methods for enhancing bone formation |
| 03/11/2004 | WO2004019882A2 METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE TAFIa ACTIVITY, COMPOUNDS, AND METHODS OF USING THE COMPOUNDS |
| 03/11/2004 | WO2004019879A2 Motilide compounds |
| 03/11/2004 | WO2004019876A2 Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure |
| 03/11/2004 | WO2004019874A2 Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma |
| 03/11/2004 | WO2004019873A2 Methods of promoting osteogenesis |
| 03/11/2004 | WO2004019870A2 Breath freshening and oral cleansing product using salicylaldehyde |
| 03/11/2004 | WO2004019869A2 Indoles having anti-diabetic activity |
| 03/11/2004 | WO2004019868A2 N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| 03/11/2004 | WO2004019866A2 Compositions and methods for treating cardiovascular disease |
| 03/11/2004 | WO2004019863A2 Combination therapy for treatment of fibrotic disorders |
| 03/11/2004 | WO2004019837A1 Medicinal product packaging |
| 03/11/2004 | WO2004019800A2 Breath freshening and oral cleansing product |
| 03/11/2004 | WO2004019762A2 Deflectable spacer for use as an interspinous process implant and method |
| 03/11/2004 | WO2004019758A2 Methods of treating idiopathic pulmonary fibrosis |
| 03/11/2004 | WO2004009578A3 Pentacyclic oxepines and derivatives thereof, process for their preparation and pharmaceutical compositions containing them |
| 03/11/2004 | WO2004004705A3 Pharmaceutical formulations for preparing drink products |
| 03/11/2004 | WO2004004699A3 Use of dantrolene, a ryanodine antagonist, in treating neural injury |
| 03/11/2004 | WO2004002462A3 Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder |
| 03/11/2004 | WO2004000789A9 Amide linker peroxisome proliferator activated receptor modulators |
| 03/11/2004 | WO2004000219A3 Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof |
| 03/11/2004 | WO2003106380A3 Fluorobenzamides suitable for the treatment of alzheimer's disease or senile dementia |
| 03/11/2004 | WO2003104192A3 Controlled release formulation of lamotrigine |
| 03/11/2004 | WO2003101923A3 Policosanol compositions, extraction from novel sources, and uses thereof |
| 03/11/2004 | WO2003101452A8 Process for the preparation of highly pure rabeprazole sodium salt |
| 03/11/2004 | WO2003099759A8 Preparation and application of transhintotalphenolic acid |
| 03/11/2004 | WO2003099200A3 Composition and method for the treatment of diaper rash using natural products |
| 03/11/2004 | WO2003097698A8 Treatment of cancer by the use of anti fas antibody |
| 03/11/2004 | WO2003097657A9 An antimicrobial agent |
| 03/11/2004 | WO2003096782A3 Process for preparing maytansinol |
| 03/11/2004 | WO2003094929A3 Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents |
| 03/11/2004 | WO2003094840A3 Induction of antigen specific immunologic tolerance |
| 03/11/2004 | WO2003092629A3 Methods of simultaneously treating mucositis and fungal infection |
| 03/11/2004 | WO2003092599A3 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| 03/11/2004 | WO2003091264A3 Non nucleoside reverse transcriptase inhibitors |
| 03/11/2004 | WO2003090679A3 11-deoxy azalide antibacterials |
| 03/11/2004 | WO2003089615A3 Antiviral inhibitions of capsid proteins |
| 03/11/2004 | WO2003088915A3 Novel sodium channel blockers |
| 03/11/2004 | WO2003086308A3 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 03/11/2004 | WO2003084520A3 Pharmaceutical preparation containing oxycodone and naloxone |
| 03/11/2004 | WO2003084504A3 Matrix for sustained, invariant and independent release of active compounds |
| 03/11/2004 | WO2003084342A3 Method and dietary composition for improving lipid digestibility |
| 03/11/2004 | WO2003082861A3 Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases |
| 03/11/2004 | WO2003075899A3 Combinations comprising epothilone derivatives and alkylating agents |
| 03/11/2004 | WO2003072737A3 Biological inhibitions induced by contact inhibitory factor |
| 03/11/2004 | WO2003068261A3 Means and methods for altering the motility of the gastrointestinal tract |
| 03/11/2004 | WO2003068164A3 Dosing regimen for gemcitabine hcv therapy |
| 03/11/2004 | WO2003068162A3 Modified fluorinated nucleoside analogues |
| 03/11/2004 | WO2003066587A3 Piperidine or pyrrolidine derivatives having an aminoacyl substituted side chain as melancortin-4 receptor agonists |
| 03/11/2004 | WO2003065789A3 N-biphenylmethyl aminocycloalkanecarboxamide derivatives |